Bacteraemia Pipeline Insight | Companies – XBiotech, LegoChem Biosciences, Basilea Pharmaceutica, ContraFect, Merck & Co., Entasis Therapeutics, Melinta Therapeutics, GlaxoSmithKline, and Others
DelveInsight’s, “Bacteremia Pipeline Insight 2023” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in the Bacteremia pipeline landscape. It covers the Bacteremia pipeline drug profiles, including Bacteremia clinical trials and nonclinical stage products. It also covers the Bacteremia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Bacteremia Pipeline treatment landscape of the report, click here @ Bacteremia Pipeline Outlook
Key Takeaways from the Bacteremia Pipeline Report
- DelveInsight’s Bacteremia Pipeline report depicts a robust space with 7+ active players working to develop 7+ pipeline therapies for Bacteremia.
- The leading Bacteremia Companies include XBiotech, LegoChem Biosciences, Basilea Pharmaceutica, ContraFect, Merck & Co., Cumberland Pharmaceuticals, Theravance Biopharma, Entasis Therapeutics, Melinta Therapeutics, GlaxoSmithKline, Cubist Pharmaceuticals LLC, and others
- Promising Bacteremia Pipeline Therapies include Daptomycin, Comparator, Ceftobiprole medocaril, Ethambutol hydrochloride, Clarithromycin, Rifabutin, MBI 226, Linezolid, Vancomycin, Oxacillin, Dicloxacillin, and others
- In Bacteremia Report, detailed description of the drug is given which includes mechanism of action of the drug, Bacteremia clinical trials studies, Bacteremia NDA approvals (if any), and product development activities comprising the technology, Bacteraemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
- The companies and academics are working to assess challenges and seek opportunities that could influence Bacteraemia R&D. The therapies under development are focused on novel approaches to treat/improve Bacteraemia.
- In July 2021 Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera (ceftobiprole) covering Russia and the Eurasian Economic Union.
- In October 2021 Zai lab and Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase III ATTACK trial.
- In February 2020 ContraFect Announces US FDA Granted Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis.
For further information, refer to the detailed Bacteremia Unmet Needs, Bacteremia Market Drivers, and Bacteremia Market Barriers, click here for Bacteremia Ongoing Clinical Trial Analysis
Bacteremia Overview
Bacteremia refers to the presence of live bacteria in the bloodstream. It can develop asymptomatically during routine activities such as brushing one’s teeth or following minor medical treatments. Release of bacterial toxins into the bloodstream, can trigger a strong immunological response, resulting in systemic inflammatory response syndrome. Another term which can be used for Bacteraemia is “Blood Poisoning”.
Request a sample and discover the recent advances in Bacteremia Ongoing Clinical Trial Analysis and Medications, click here @ Bacteremia Treatment Landscape
Bacteremia Emerging Drugs Profile
- Ceftobiprole medocaril : Basilea Pharmaceutica
Ceftobiprole medocaril is the water-soluble prodrug of the pyrrolidinone cephalosporin, ceftobiprole. It is developed for IV administration. It exhibits extensive antibacterial action against Gram-positive and Gram-negative bacteria, including methicillin-resistant staphylococci, penicillin-resistant pneumococci, and Enterococcus faecalis. A unique combination of properties in ceftobiprole medocaril inhibits all transpeptidases, including the penicillin-binding protein (PBP) 2a. It is designed specifically to bind to this penicillin-resistant target. In January 2022 Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections. A phase 3 Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis.
- Exebacase : ContraFect
Exebacase (CF301) is a lysine with potent activity against Staphylococcus aureus. It has the potential to become a new first-line treatment for patients with staphylococcal bacteremia. It targets a highly conserved region of the cell wall, which is important for bacteria, making it less likely that resistance will develop. When used in combination with SOC antibiotics, the result is a new therapeutic modality capable of addressing the high unmet clinical need for Staph aureus infections. It was the first and only lysine to enter a human clinical trial in the United States. Adding exebacase to vancomycin or daptomycin significantly increased survival in animal models of the disease compared with treatment with SOC antibiotics or exebacase alone. A Phase III Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis.
Dive deep into rich insights for drugs for Bacteremia Market Drivers and Bacteremia Market Barriers, click here @ Bacteremia Unmet Needs and Analyst Views
Bacteremia Pipeline Therapeutics Assessment
There are approx. 7+ Bacteremia companies which are developing the Bacteremia therapies. The Bacteremia companies which have their Bacteremia drug candidates in the most advanced stage, i.e. phase III include, Basilea Pharmaceutica.
Scope of the Bacteremia Pipeline Report
- Coverage- Global
- Bacteremia Companies- XBiotech, LegoChem Biosciences, Basilea Pharmaceutica, ContraFect, Merck & Co., Cumberland Pharmaceuticals, Theravance Biopharma, Entasis Therapeutics, Melinta Therapeutics, GlaxoSmithKline, Cubist Pharmaceuticals LLC, and others
- Bacteremia Pipeline Therapies- Daptomycin, Comparator, Ceftobiprole medocaril, Ethambutol hydrochloride, Clarithromycin, Rifabutin, MBI 226, Linezolid, Vancomycin, Oxacillin, Dicloxacillin, and others.
- Bacteremia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Bacteremia Mergers and acquisitions, Bacteremia Licensing Activities @ Bacteremia Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Executive Summary
- Bacteremia: Overview
- Bacteremia Pipeline Therapeutics
- Therapeutic Assessment
- Bacteremia – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Ceftobiprole medocaril : Basilea Pharmaceutica
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Delpazolid : LegoChem Biosciences
- Bacteremia Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- 514G3 : XBiotech
- Drug profiles in the detailed report…..
- Inactive Products
- Bacteremia Key Companies
- Bacteremia Key Products
- Bacteremia – Unmet Needs
- Bacteremia – Market Drivers and Barriers
- Bacteremia – Future Perspectives and Conclusion
- Bacteremia Analyst Views
- Bacteremia Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
